Juan S. Lasa

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 208 citations

Systemic Treatment, Golimumab Monotherapy, Gastroenterology +4

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 62 citations · Full text

Placebo-controlled Induction, Gastroenterology, Pathology +6

Risk of colorectal neoplasia in patients with celiac disease: A multicenter study

Lisandro Pereyra, Raquel González, Adriana Mohaidle et al. · Journal of Crohn s and Colitis · 2013 · 32 citations · Full text

Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study

Luis Maria Bustos Fernández, Fernando Man, Juan S. Lasa · Digestive Diseases · 2023 · 25 citations

HELICOBACTER PYLORI PREVALENCE IN PATIENTS WITH CELIAC DISEASE: results from a cross-sectional study

Juan S. Lasa, Ignacio Zubiaurre, Guillermo Dima et al. · Arquivos de Gastroenterologia · 2015 · 24 citations · Full text